vs
Amphastar Pharmaceuticals, Inc.（AMPH）とGRID DYNAMICS HOLDINGS, INC.（GDYN）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $104.1M、GRID DYNAMICS HOLDINGS, INC.の約1.8倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -1.4%、差は14.8%）。GRID DYNAMICS HOLDINGS, INC.の前年同期比売上増加率が高い（3.7% vs -1.8%）。過去8四半期でGRID DYNAMICS HOLDINGS, INC.の売上複合成長率が高い（12.0% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Escape Dynamics Inc.はコロラド州に本拠を置くテクノロジー企業で、2010年から2015年にかけて事業を展開し、単段軌道投入可能で電磁駆動の再利用可能なスペースプレーンの市場投入を目指し開発を行っていました。
AMPH vs GDYN — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $104.1M |
| 純利益 | $24.4M | $-1.5M |
| 粗利率 | 46.8% | 34.8% |
| 営業利益率 | 19.4% | 61.7% |
| 純利益率 | 13.3% | -1.4% |
| 売上前年比 | -1.8% | 3.7% |
| 純利益前年比 | -35.7% | -150.6% |
| EPS（希薄化後） | $0.51 | $-0.02 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $104.1M | ||
| Q4 25 | $183.1M | $106.2M | ||
| Q3 25 | $191.8M | $104.2M | ||
| Q2 25 | $174.4M | $101.1M | ||
| Q1 25 | $170.5M | $100.4M | ||
| Q4 24 | $186.5M | $100.3M | ||
| Q3 24 | $191.2M | $87.4M | ||
| Q2 24 | $182.4M | $83.0M |
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $24.4M | $306.0K | ||
| Q3 25 | $17.4M | $1.2M | ||
| Q2 25 | $31.0M | $5.3M | ||
| Q1 25 | $25.3M | $2.9M | ||
| Q4 24 | $38.0M | $4.5M | ||
| Q3 24 | $40.4M | $4.3M | ||
| Q2 24 | $37.9M | $-817.0K |
| Q1 26 | — | 34.8% | ||
| Q4 25 | 46.8% | 34.0% | ||
| Q3 25 | 51.4% | 33.3% | ||
| Q2 25 | 49.6% | 34.1% | ||
| Q1 25 | 50.0% | 36.8% | ||
| Q4 24 | 46.5% | 36.9% | ||
| Q3 24 | 53.3% | 37.4% | ||
| Q2 24 | 52.2% | 35.6% |
| Q1 26 | — | 61.7% | ||
| Q4 25 | 19.4% | 0.5% | ||
| Q3 25 | 13.2% | -0.2% | ||
| Q2 25 | 24.2% | -0.1% | ||
| Q1 25 | 21.9% | -2.0% | ||
| Q4 24 | 24.2% | 1.3% | ||
| Q3 24 | 29.8% | 2.4% | ||
| Q2 24 | 30.3% | 0.0% |
| Q1 26 | — | -1.4% | ||
| Q4 25 | 13.3% | 0.3% | ||
| Q3 25 | 9.0% | 1.1% | ||
| Q2 25 | 17.8% | 5.2% | ||
| Q1 25 | 14.8% | 2.9% | ||
| Q4 24 | 20.4% | 4.5% | ||
| Q3 24 | 21.1% | 4.9% | ||
| Q2 24 | 20.8% | -1.0% |
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.51 | $0.01 | ||
| Q3 25 | $0.37 | $0.01 | ||
| Q2 25 | $0.64 | $0.06 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.06 | ||
| Q3 24 | $0.78 | $0.05 | ||
| Q2 24 | $0.73 | $-0.01 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $327.5M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $530.1M |
| 総資産 | $1.6B | $605.0M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $327.5M | ||
| Q4 25 | $282.8M | $342.1M | ||
| Q3 25 | $276.2M | $338.6M | ||
| Q2 25 | $231.8M | $336.8M | ||
| Q1 25 | $236.9M | $325.5M | ||
| Q4 24 | $221.6M | $334.7M | ||
| Q3 24 | $250.5M | $231.3M | ||
| Q2 24 | $217.8M | $256.0M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $530.1M | ||
| Q4 25 | $788.8M | $542.1M | ||
| Q3 25 | $776.7M | $537.7M | ||
| Q2 25 | $757.5M | $532.2M | ||
| Q1 25 | $751.3M | $517.4M | ||
| Q4 24 | $732.3M | $517.8M | ||
| Q3 24 | $727.7M | $400.2M | ||
| Q2 24 | $713.3M | $388.4M |
| Q1 26 | — | $605.0M | ||
| Q4 25 | $1.6B | $612.9M | ||
| Q3 25 | $1.7B | $613.2M | ||
| Q2 25 | $1.6B | $608.9M | ||
| Q1 25 | $1.6B | $590.9M | ||
| Q4 24 | $1.6B | $592.2M | ||
| Q3 24 | $1.5B | $477.3M | ||
| Q2 24 | $1.5B | $443.6M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $9.9M | ||
| Q3 25 | $52.6M | $7.0M | ||
| Q2 25 | $35.6M | $14.4M | ||
| Q1 25 | $35.1M | $9.4M | ||
| Q4 24 | $29.0M | $7.1M | ||
| Q3 24 | $60.0M | $9.2M | ||
| Q2 24 | $69.1M | $10.7M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $6.1M | ||
| Q3 25 | $47.2M | $2.9M | ||
| Q2 25 | $25.0M | $10.2M | ||
| Q1 25 | $24.4M | $6.0M | ||
| Q4 24 | $16.6M | $4.4M | ||
| Q3 24 | $46.2M | $5.9M | ||
| Q2 24 | $63.1M | $8.0M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 5.7% | ||
| Q3 25 | 24.6% | 2.8% | ||
| Q2 25 | 14.3% | 10.1% | ||
| Q1 25 | 14.3% | 6.0% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 6.8% | ||
| Q2 24 | 34.6% | 9.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 3.6% | ||
| Q3 25 | 2.8% | 3.9% | ||
| Q2 25 | 6.1% | 4.1% | ||
| Q1 25 | 6.3% | 3.3% | ||
| Q4 24 | 6.7% | 2.6% | ||
| Q3 24 | 7.2% | 3.7% | ||
| Q2 24 | 3.3% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 32.34× | ||
| Q3 25 | 3.03× | 5.92× | ||
| Q2 25 | 1.15× | 2.73× | ||
| Q1 25 | 1.39× | 3.21× | ||
| Q4 24 | 0.76× | 1.56× | ||
| Q3 24 | 1.48× | 2.15× | ||
| Q2 24 | 1.82× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GDYN
セグメントデータなし
